Thomas Yau

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 494 citations · Full text

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim et al. · Journal of Hepatology · 2019 · 267 citations · Full text

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma

Ho Yeong Lim, Philippe Merle, Karl Weiss et al. · Clinical Cancer Research · 2018 · 78 citations · Full text

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 71 citations · Full text

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Patrick Mollon, Jean‐Frédéric Blanc et al. · Advances in Therapy · 2020 · 56 citations · Full text